|
May 12
|
Pluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)
|
|
May 2
|
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
|
|
Apr 8
|
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
|
|
Mar 28
|
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
|
|
Mar 27
|
Pluri Inc. Announces 1-for-8 Reverse Share Split
|
|
Mar 21
|
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
|
|
Mar 19
|
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
|
|
Mar 14
|
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
|
|
Mar 11
|
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
|
|
Mar 6
|
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
|
|
Jan 23
|
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
|
|
Dec 21
|
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
|
|
Apr 27
|
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
|